Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver ...

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...

Researchers have found in a randomized trial in China that dapagliflozin, an SGLT2 inhibitor, improved metabolic ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Health experts warn about the silent rise of chronic liver disease, urging for immediate actions in detection and treatment ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.